Effect of peramivir on respiratory symptom improvement in patients with respiratory disease -comparatve evaluation: peramivir maximal dose (600mg) repeat-dosing (2days) vs standard dose (300mg) single-dosing vs oseltamivir (75mg bid) 5days treatment
Not Applicable
- Conditions
- Influenza A and B virus infected patient with chronic respiratory disease(asthma, COPD, pulmonary fibrosis)
- Registration Number
- JPRN-UMIN000030118
- Lead Sponsor
- Shionogi&Co.,LTD
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 210
Inclusion Criteria
Not provided
Exclusion Criteria
1)Patients who need antibacterial or antifungal or antiviral drugs for treatment of underlying dieases 2)patients with chronic respiratory who had been in ventilator settings 3)patients receving dialysis or with impaired renal function (Ccr<50mL/min) 4)within previously 7days, patients who were treated with either of 4NA inhibitor (oseltamivir, zanamivir, peramivir and laninamivir)and amantadine 5)pregnant, breast-feeding woman
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method